Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Optimal infection prophylaxis strategy for relapsed/refractory multiple myeloma patients undergoing elranatamab therapy (OPTIMUS-EL)

Ja Min Byun, Dong Hyun Kim, Youngil Koh, Chang-Ki Min, Kihyun Kim, Hee Jeong Cho, Ji Yun Lee

Blood (2025) 146 (Supplement 1): 8237.

https://doi.org/10.1182/blood-2025-8237

Published: 2025

Journal Articles

MagnetisMM-6 part 2: A phase 3, open-label, randomized study of elranatamab in combination with daratumumab and lenalidomide vs daratumumab, lenalidomide, and dexamethasone in transplant-ineligible or -deferred patients with newly diagnosed multiple myeloma

Ja Min Byun, Meletios Dimopoulos, Eeman Shaikh, Karen Gogat-Marchant, Nina N. Green, Domenico Cieri, Hang Quach

Blood (2025) 146 (Supplement 1): 5845.

https://doi.org/10.1182/blood-2025-5845

Published: 2025

Journal Articles

Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Initial results from part 1

Ja Min Byun, Chang-Ki Min, Kihyun Kim, Dok Hyun Yoon, Sung-Hoon Jung, Wee-Joo Chng, Chandramouli Nagarajan, Youngil Koh

Blood (2025) 146 (Supplement 1): 5835.

https://doi.org/10.1182/blood-2025-5835

Published: 2025

Journal Articles

A clinical overview of infection in patients receiving elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) for newly diagnosed multiple myeloma in the MagnetisMM-6 trial

Ja Min Byun, Ludek Pour, Jiri Minarik, H. Miles Prince, Elham Askari, Su-Peng Yeh, Albert Oriol, Satoshi Ito, Darrel White, Eeman Shaikh, Nina N. Green, Eric Leip, Andrea Viqueira, Hang Quach

Blood (2025) 146 (Supplement 1): 2253.

https://doi.org/10.1182/blood-2025-2253

Published: 2025

Journal Articles

Phase 1 study of GCC2005, an allogeneic CD5-directed CAR-NK therapy, for patients with Relapsed/Refractory NK/T-cell malignancies

Won-Seog Kim, Dok Hyun Yoon, Youngil Koh, Seok Jin Kim, Sang Eun Yoon, Hyungwoo Cho, Jaewon Hyung, Ja Min Byun, Hyesung Jeon, Seungryel Han

Blood (2025) 146 (Supplement 1): 1043.

https://doi.org/10.1182/blood-2025-1043

Published: 2025

Journal Articles

Old mismatched donors are associated with inferior outcomes after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndrome, but not in Acute Myeloid Leukemia

Dong Hyun Kim, Ja Min Byun, Dong-Yeop Shin, Youngil Koh, Inho Kim, Sung-Soo Yoon, Hyo Jung Kim, Junglim Lee, Junshik Hong

Blood (2025) 146 (Supplement 1): 6052.

https://doi.org/10.1182/blood-2025-6052

Published: 2025

Journal Articles

Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study

Blood (2024) 144 (Supplement 1): 3369.

https://doi.org/10.1182/blood-2024-199733

Published: 2024

Journal Articles

ATR Inhibitor Elimusertib Suppresses Drug Persister Clones in TP53 -Mutated Acute Myeloid Leukemia Via CGAS-Sting-Mediated Cell Death

Dongchan Kim, Daehyeon Gwak, Ja Min Byun, Youngil Koh, Junshik Hong, Jung Lim Lee, Sung-Soo Yoon, Dong-Yeop Shin

Blood (2024) 144 (Supplement 1): 1375.

https://doi.org/10.1182/blood-2024-202733

Published: 2024

Journal Articles

Spectrum of TP53 Mutation in Hematologic Malignancies

Seo Yoon Jang, Joowon Jang, Jee-Soo Lee, Songyi Park, Ja Min Byun, Youngil Koh, Junshik Hong, Inho Kim, Sung-Soo Yoon, Dong-Yeop Shin

Blood (2024) 144 (Supplement 1): 5731.

https://doi.org/10.1182/blood-2024-210051

Published: 2024

Journal Articles

A Phase II Clinical Study for Evaluating the Efficacy and Safety of Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone in Transplantation-Eligible Elderly Patients with Newly Diagnosed Multiple Myeloma (KMM2101)

Sang Eun Yoon, Sung-Hoon Jung, Gyeong Won Lee, Chang-Ki Min, Ja Min Byun, Jae-Yong Kwak, Myung-Won Lee, Ho Sup Lee, Seok Jin Kim, Kihyun Kim

Blood (2024) 144 (Supplement 1): 7045.

https://doi.org/10.1182/blood-2024-198947

Published: 2024

Journal Articles

Rh Antigens Immunogenicity Prediction Using in silico analysis of HLA Binding

Hee-Jeong Youk, Yong-Joon Cho, Ja Min Byun, Yong-Hyun Han, Seong Who Kim, Dae-Hyun Ko

Blood (2024) 144 (Supplement 1): 4028.

https://doi.org/10.1182/blood-2024-202747

Published: 2024

Journal Articles

Efficacy and Safety of T-Cell Engagers Compared to Standard of Care for Relapsed/Refractory Multiple Myeloma Treatment: A Real-World RCT Mimicking Analyses

Ja Min Byun, Sung-Soo Park, Suein Choi, Youngil Koh, Chang-Ki Min, Seunghoon Han

Blood (2024) 144 (Supplement 1): 4707.

https://doi.org/10.1182/blood-2024-198337

Published: 2024

Journal Articles

Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment

Blood (2024) 144 (Supplement 1): 4698.

https://doi.org/10.1182/blood-2024-205164

Published: 2024

Journal Articles

Unraveling TP53 -Mutated Acute Myeloid Leukemia : Clinical Insights and Genetic Profiles

Songyi Park, Sang-A Kim, Ji Yun Lee, Ja Min Byun, Jeong-Ok Lee, Youngil Koh, Junshik Hong, Junglim Lee, Soo-Mee Bang, Inho Kim, Sung-Soo Yoon, Dongyeop Shin

Blood (2024) 144 (Supplement 1): 5944.

https://doi.org/10.1182/blood-2024-202293

Published: 2024

Journal Articles

T-Cell Depletion with Both Reduced Dose Anti-Thymocyte Globulin and Reduced Dose Post-Transplant Cyclophosphamide in Haploidentical Peripheral Blood Stem Cell Transplantation for Acute Leukemia and Myelodysplatic Syndrome

Junshik Hong, Dong Hyun Kim, Ja Min Byun, Dongyeop Shin, Youngil Koh, Inho Kim, Sung-Soo Yoon, Hyun Jung Lee, Jung Lim Lee

Blood (2023) 142 (Supplement 1): 7000.

https://doi.org/10.1182/blood-2023-185845

Published: 2023

Journal Articles

Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment

Blood (2023) 142 (Supplement 1): 3359.

https://doi.org/10.1182/blood-2023-179170

Published: 2023

Journal Articles

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Blood (2023) 142 (Supplement 1): 4746.

https://doi.org/10.1182/blood-2023-177968

Published: 2023

Journal Articles

Cardiovascular Toxicity after Carfilzomib, Lenalidomide, and Dexamethasone Combination Chemotherapy in the Real-World 364 Asian Multiple Myeloma Patients on Behalf of the Korean Multiple Myeloma Working Party (KMM2201 study)

Blood (2023) 142 (Supplement 1): 6675.

https://doi.org/10.1182/blood-2023-174439

Published: 2023

Journal Articles

Serum Erythropoietin As an Early Marker for Hidden Hematologic Malignancy in Anemia of Unknown Etiology

Seong Juyong, Dong-Yeop Shin, Ja Min Byun, Youngil Koh, Junshik Hong, Inho Kim, Sung-Soo Yoon

Blood (2022) 140 (Supplement 1): 8164–8165.

https://doi.org/10.1182/blood-2022-155698

Published: 2022

Journal Articles

A Prospective Randomized Study for Optimal Red Blood Cell Use Patients with Acute Myeloid Leukemia Receiving Dose Intensive Chemotherapy

Ja Min Byun, Junshik Hong, Dong-Yeop Shin, Youngil Koh, Sung-Soo Yoon, Inho Kim, Hyungsuk Kim

Blood (2022) 140 (Supplement 1): 81–82.

https://doi.org/10.1182/blood-2022-157619

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Optimal infection prophylaxis strategy for relapsed/refractory multiple myeloma patients undergoing elranatamab therapy (OPTIMUS-EL)

MagnetisMM-6 part 2: A phase 3, open-label, randomized study of elranatamab in combination with daratumumab and lenalidomide vs daratumumab, lenalidomide, and dexamethasone in transplant-ineligible or -deferred patients with newly diagnosed multiple myeloma

Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Initial results from part 1

A clinical overview of infection in patients receiving elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) for newly diagnosed multiple myeloma in the MagnetisMM-6 trial

Phase 1 study of GCC2005, an allogeneic CD5-directed CAR-NK therapy, for patients with Relapsed/Refractory NK/T-cell malignancies

Old mismatched donors are associated with inferior outcomes after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndrome, but not in Acute Myeloid Leukemia

Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study

ATR Inhibitor Elimusertib Suppresses Drug Persister Clones in TP53 -Mutated Acute Myeloid Leukemia Via CGAS-Sting-Mediated Cell Death

Spectrum of TP53 Mutation in Hematologic Malignancies

A Phase II Clinical Study for Evaluating the Efficacy and Safety of Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone in Transplantation-Eligible Elderly Patients with Newly Diagnosed Multiple Myeloma (KMM2101)

Rh Antigens Immunogenicity Prediction Using in silico analysis of HLA Binding

Efficacy and Safety of T-Cell Engagers Compared to Standard of Care for Relapsed/Refractory Multiple Myeloma Treatment: A Real-World RCT Mimicking Analyses

Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment

Unraveling TP53 -Mutated Acute Myeloid Leukemia : Clinical Insights and Genetic Profiles

T-Cell Depletion with Both Reduced Dose Anti-Thymocyte Globulin and Reduced Dose Post-Transplant Cyclophosphamide in Haploidentical Peripheral Blood Stem Cell Transplantation for Acute Leukemia and Myelodysplatic Syndrome

Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Cardiovascular Toxicity after Carfilzomib, Lenalidomide, and Dexamethasone Combination Chemotherapy in the Real-World 364 Asian Multiple Myeloma Patients on Behalf of the Korean Multiple Myeloma Working Party (KMM2201 study)

Serum Erythropoietin As an Early Marker for Hidden Hematologic Malignancy in Anemia of Unknown Etiology

A Prospective Randomized Study for Optimal Red Blood Cell Use Patients with Acute Myeloid Leukemia Receiving Dose Intensive Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only